NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $172 million versus the consensus estimate of $173.05 million.

GUIDANCE:

NeoGenomics sees FY2025 revenue of $735-745 million, versus the consensus of $735 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
• Bernstein SocGen on DoorDash Inc. (DASH): 'What now for the stock?'
• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance